A revolution in the treatment of non-Hodgkin's lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 4, 1998, Pages 213-223

  DeNardo, G L ^a   O'Donnell, R T ^b   Oldham, R K ^b   DeNardo, S J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B1; MONOCLONAL ANTIBODY CDB8; MONOCLONAL ANTIBODY LYM 1; ONCOLYM; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT OUTCOME;

EID: 0031730693     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.213     Document Type: Review

References (60)

1. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U S. Cancer 1998;82(6):1197-1207.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CAJ, Miller TP Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993,328:1002-1006
3. Longo DL, Duffey PL. Management of aggressive histology lymphoma. An approach based on data from the National Cancer Institute. Hem One Annals 1993;1:19-28
4. Gordon LI, Harrington D, Anderson J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349.
5. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147-3154.
6. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985;65:1349-1363.
7. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, Peng J-S, McGahan JP. Treatment of a patient with B cell lymphoma by 1-131 Lym-1 monoclonal antibodies. Int J Biol Markers 1987;2. 49-53.
8. DeNardo SJ, DeNardo GL, O'Grady LF, Hu E, Sytsma VM, Mills SL, Levy NB, Macey DJ, Miller CH, Epstein AL. Treatment of B cell malignancies with 1-131 Lym-1 monoclonal antibodies. Int J Cancer 1988;3 Suppl (3).96-101.
9. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1994;73:1425-1432.
10. Scheinberg DA, Strauss DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression J Clin Oncol 1990,8:792-803.
11. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, et al Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 1996;14:1974-1981.
12. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, Grillo-Lopez AJ, Chinn P, Vams C, Ning S-C, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2 457-470.
13. 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconjug Radiopharm 1993;6:1-11.
14. Kuzel T, Rosen ST, Zimmer AM, Silverstein EA, Spies S, Saletan SL, Norvitch ME, Birkhofer M, Shochat D, LoBuglio AF, et al. A phase 1 escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1 Cancer Biother 1993;8:3-16.
15. White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 1996,87 3640-3649.
16. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, et al Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991,9:548-564.
17. Juweid M, Sharkey RM, Markowitz A, Behr TM, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung SO, Rubin AD, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995, 55(23).5899s-5907s.
18. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase 1 dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993.11 2021-2029.
19. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, et al. Phase II trial of 13 II-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 1995; 346:336-340
20. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko GM, Fisher LD, Porter B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 1993;329:1219-1224.
21. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 1997,15:3266-3274.
22. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhard JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90(6):2188-2195.
23. Knox SJ, Goris ML, Wessels BW. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol 1992; 23:111-117.
24. 90Y lymphoma therapy Cancer 1994;73 Suppl(3):966-973.
25. Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG. Gumerlock PH. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer 1997;80 Suppl(12):2706-2712.
26. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261-1269
27. 131I-Lym-1. Cancer Res 1990;50 Suppl(3):1014-1016.
28. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russel C, Colcher D, Schlom J, Shochat D, LoBuglio AF. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer J Nucl Med 1992,33:1648-1653
29. Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, Houchens DP, Colcher D Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82:763-771.
30. DeNardo GL, DeNardo SJ Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer In:Radioimmunoimaging and Radioimmunotherapy Burchiel SW, Rhodes BA(eds) Elsevier Science Publishing Co., Inc. New York, 1983; 41-62.
31. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
32. 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model Int J Cancer 1988,41:127-134.
33. Buchsbaum DJ, Khazaeli MB, Liu TP, Bright S. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 1-131-labeled monoclonal antibody CC49 Cancer Res 1995;55 Suppl:5881-5887.
34. DeNardo SJ, DeNardo GL, O'Grady LF, Levy NB, Mills SL, Macey DJ, McGahan JP, Miller CH, Epstein AL. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjug Radiopharm 1988;1:17-33.
35. Reff ME, Camer C, Chambers KS, China PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-445.
36. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12(3):177-186.
37. Rituxan, full prescribing information. 1997; December. San Diego, CA: IDEC Pharmaceuticals Corporation.
38. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Radiolabeled antibody therapy of lymphomas. In:Biologic Therapy of Cancer, DeVita VT, Jr., Hellman S, Rosenberg SA(eds) J.B. Lippincott Company, Philadelphia, 1994; pp 1-13.
39. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW, Taylor CR. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-840.
40. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26-30
41. Hu E, Epstein AL, Naeve GS, Gill I, Martin S, Sherrod A, Nichols P, Chen D, Mazumder A, Levine AM. A phase 1a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies Hematol Oncol 1989;7:155-166.
42. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;In Press
43. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;In Press
44. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
45. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake Cancer Res 1996;56:4998-5004
46. 131I-Lym-1 as a model. Cancer 1994;73 Suppl:1038-1048
47. DeNardo GL, DeNardo SJ, Meares CF, Kukis DL, Diril H, McCall MJ, Adams GP, Mausner LF, Moody DC, Deshpande SV. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and patients with lymphoma. Antibody Immunoconjug Radiopharm 1991;4:777-785
48. Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MJ, DeNardo GL, Meares CF Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473-479.
49. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3:71-79
50. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl A Med 1998.In Press
51. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996;14:1383-1400.
52. 67Cu-2IT-BAT-Lym-1 for fractional radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res 1998;In Press
53. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, et al. A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329.987-994.
54. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer 1997;80 Suppl:2706-2711.
55. Lamborn KR, DeNardo GL, DeNardo SJ, Goldstein DS, Shen S, Larkin EC, Kroger LA. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 1997;3:1253-1260.
56. Dillman RO.Magic bullets at last! Finally-approval of a monoclonal antibody for the treatment of cancer. Cancer Biother Radiopharm 1997;12(4):223-225.
57. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid M, et al. Advantages of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44(3):179-188.
58. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase T study. Blood 1995;85(12):3457-3465.
59. Oldham RK. Cancer and diabetes: are there similarities? Cancer Biother Radiopharm 1997;12(1):1-3.
60. Principles of cancer biotherapy. 2nd ed. Oldham RK, editor New York: Marcel Dekker; 1991.